Schering-Plough's Temodar Gets Priority Review For First-Line Glioma

The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet